MAL oral / D&A Pharma - LARVOL DELTA

Patient and caregiver treatment preferences for ALK+ non-small cell lung cancer in the United States. (ASCO 2025) - "Patients and caregivers highly prioritized achieving a higher chance of 3-year PFS when choosing treatments. Most were willing to trade PFS benefit for reduced risks, although there was a subset of caregivers who were unwilling to trade any benefit for reduced risks. The extent varied between patients and caregivers."

Clinical • Lung Cancer • Musculoskeletal Pain • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor

"Y avait un très bon post de @vlsdirect sur LinkedIn au sujet de la pharmacovigilance, le schéma attaché était pas mal" (@StephLaSaleBete)

Adverse events

"cansada de não poder nem respirar dentro da padaria sem passar mal e as pessoas acharem que eu tô fazendo dieta pra emagrecer ou que eu sou vegana @TakedaPharma acelera essa cura aí" (@cruzcredoyumi)

"Der Weg zum #Traumberuf ist selten gerade & einfach, sondern auch mal kurvenreich. Lernen Sie Niklas Schäfer kennen, der als #Pharmakant bei @TakedaPharma seine Berufung gefunden hat & in der Chemiebranche elementare Vielfalt erlebt 🧬💊! 05.04. anmelden👉https://t.co/tUvusZFBDg" (@SWBWnews)

"Pero si no tienen un duro pa invertir , estan quebrados .madre mia lo que hay que leer, otro dardo mal intencionado para joder a pharma" (@BenaventRubio)